Predictors of Poor Seroconversion and Adverse Events Associated With the COVID-19 mRNA BNT162b2 Vaccine in Cancer Patients on Active Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer